NCT05549219View on ClinicalTrials.gov

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pmm2-CDGPhosphomannomutase 2 Deficiency
Interventions
DRUG

GLM101

GLM101 IV Infusion

Trial Locations (4)

33606

Clinical Research of West Florida, Tampa

55905

Mayo Clinic, Rochester

08950

Hospital Sant Joan de Déu, Barcelona

WC1N3JH

Great Ormond Street Hospital, London

Sponsors

Lead Sponsor

Glycomine, Inc.
All Listed Sponsors
lead

Glycomine, Inc.

INDUSTRY

NCT05549219 - 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG | Biotech Hunter | Biotech Hunter